Company / Operating Income
Avalo Therapeutics, Inc. Operating Income History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$72.9M
FY2025
5-year range
-$82.1M / -$27.4M
FY2021-FY2025
Trend
-6.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income has fluctuated over the past 9 years, ranging from -$82M in FY2021 to $14M in FY2017.
Based on SEC 10-K filings.
-$73M in FY2025.
Declined from -$27M to -$73M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating income decreased 6.4% year-over-year.
- Peak operating income was recorded in FY2017.
- Lowest operating income in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.59 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$72.9M | -6.4% |
| FY2024 | -$68.5M | -150.5% |
| FY2023 | -$27.4M | +26.9% |
| FY2022 | -$37.4M | +54.4% |
| FY2021 | -$82.1M | -12.8% |
| FY2020 | -$72.8M | -351.4% |
| FY2019 | -$16.1M | +54.4% |
| FY2018 | -$35.4M | -354.7% |
| FY2017 | $13.9M | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026